US3475537A - Steroid esters - Google Patents

Steroid esters Download PDF

Info

Publication number
US3475537A
US3475537A US544378A US3475537DA US3475537A US 3475537 A US3475537 A US 3475537A US 544378 A US544378 A US 544378A US 3475537D A US3475537D A US 3475537DA US 3475537 A US3475537 A US 3475537A
Authority
US
United States
Prior art keywords
acetoxy
phosphato
salt
compound
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US544378A
Other languages
English (en)
Inventor
Walter Morozowich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of US3475537A publication Critical patent/US3475537A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general

Definitions

  • This invention relates to C -phosphate esters of progestational steroids, particularly the salt forms of those corresponding to the general formula appearing below. It relates further to methods for synthesizing such phosphate esters.
  • phoshpate esters of A -3-hydroxy steroids are highly water soluble and form stable aqueous solutions and are thus chemically unique compared with poor organic esters of A -3-hydroxy steroids.
  • phosphatase enzymes readily cleave representative 3-phosphate esters of compounds falling within the formula, below, to produce the free 3- hydroxy steriod compound. This stability in aqueous solution, yet ready cleavability by phosphatase enzymes, lend to the compounds particularly advantageous properties rendering them suitable for a variety of pharmacological uses.
  • An advantage of this invention is the provision of watersoluble forms of progestational agents for intravenous administration in the treatment of threatened abortion and other circumstances requiring rapid and substantial blood levels of the agents. No such agent is at present available, and many of the oral progestational agents which are available have low water solubility, and hence do not afford complete and uniform absorption.
  • the phosphate esters of A -3-hydroxy steriods, the products of this invention, are the C -phosphate esters of the following structural formula:
  • R" -il-CNH n+1 (n is 1 to 6).
  • the phosphate esters of A -3-hydroxy steroids of this invention are hydrolytically unstable in their free acid form, but exist and are useful in their various pharmacologically acceptable salt forms, as described below.
  • the above compounds find use, particularly in their salt form, in the treatment of mammals and other animals as progestational agents. They can be administered for the purpose and in the manner and dosage forms disclosed for 17u-acetoxy progesterone in U.S. Patent 2,965,- 541; and for the purpase and in the manner and dosage forms applied to progestational compounds generally, for both oral and parenteral use. Of the latter use, intramuscual or intravenous administration is preferable.
  • This invention also includes a chemical process for the preparation of C -phosphate esters of progestational steroids containing an allylic double bond such as the A double bond.
  • the reaction in general is accomplished by causing a A -3fi-hydroxy compound, e.g., corresponding to the 3-oxy moiety of the above formula, to react in a medium comprising triethylamine, ortho phosphoric acid and trichloroacetonitrile.
  • the reaction provides the desired C -phosphate ester in one reaction step.
  • starting material used in the novei process of this invention is preferably a A -3/8-ol steriod compound which may possess any of the conventional non-interfering substituents found in compounds of the androstane and pregnane series and of the alkylated androstane and alkylated pregnane series, including those possessing double bonds in the nucleus, as are known in the art.
  • the phosphorylation process according to this invention is conducted, as described above, by treating the A 35-01 with triethylamine, ortohphosphoric acid and trichloroacetonitrile to give the desired steriod C -phosphate ester in one step.
  • the molal ratio of the three constituents of the reaction mixture in which the novel process is conducted can vary over wide ranges so long as each consituent is present in substantially reacting amounts. It is Well to avoid excesses of orthophosphoric acid in order to prevent the formation of steroid pyrophosphate esters as contaminants. It is likewise advisable to avoid excesses of triethylamine to prevent prolonged reaction times.
  • the preferred molal ratio of orthophosphoric acid to steroid is about 1:1.
  • the preferred molal ratio of triethylamine to orthophosphoric acid is about 1:1.
  • the molal amount of trichloroacetonitrile is at least equal to that of the steroid.
  • the reaction is conducted in liquid phase and preferably at atmospheric pressure. Under these conditions the temperature is not critical, but reaction times may be prolonged with temperatures substantially below 20 C.
  • the preferred initial reaction temperature lies between 50 and 80 C. for the sake of technological convenience.
  • the time required for satisfactory reaction depends upon the chemico-thermodynamic characteristics of the reaction mixture as will be readily apprehended by those skilled in the art. It is preferable to select ratios of reactants and reaction temperatures so as to effect a completed reaction in less than four hours.
  • the course of the reaction can be followed by any of the conventional means such as thin-layer chromatography or ion-exchange chromatography.
  • the desired C -phosphate ester Separation of the desired C -phosphate ester from the reaction mixture is easily achieved by conversion to the cyclohexylamine salt or other water insoluble cyclic amine salt, and this salt can be purified by recrystallization from solvents such as hot acetone-water mixtures.
  • the desired C -phosphate ester can also be recovered as the disodium salt by treatment with sodium hydroxide.
  • the potassium, lithium, ammonium or other pharmacologically acceptable salts can be prepared using the corresponding hydroxide.
  • PREPARATION 1 38.8 g. of 6a-methyl-17a-acetoxy progesterone was dissolved in 450 ml. purified tetrahydrofuran cooled to C. and mixed with a cold (0 C.) solution of 30.0 g. lithium aluminum tri-t-butoxyhydride dissolved in 150 m1. of purified tetrahydrofuran. Nitrogen atmosphere was used throughout. The solution was stirred at 0 C. for 30 minutes, then allowed to stand at room temperature for 1 /2 hours. The solution was poured into a separatory funnel containing a mixture of 125 ml. acetic acid, 600 g. chopped ice, and 400 ml. water. The mixture was extracted three times with 225-ml.
  • Example 1.3p-phosphato-17a-acetoxy-6a-methylpregn- 4-en-20-one 5 g. of crystalline phosphoric acid was dissolved in 50 ml. acetonitrile containing 0.5 ml. water by heating to 60. The solution was treated with 13.4 ml. triethylamine, 19.4 g. of Zip-hydroxy-17a-acetoxy-6a-methylpregn-4-en- 20-one and 20 ml. of trichloroacetonitrile. The resulting yellow solution was maintained at room temperature for 4 hours. The solution was diluted with 225 ml. of water and extracted with four 100 ml. portions of ether.
  • the aqueous layer was concentrated under vacuum at to a volume of 75 ml.
  • the yellow solution was treated with 5 ml. of cyclohexylamine and within a few minutes a crystalline deposit of the bis-cyclohexylammonium salt of 3/3-phosphato-17a-acetoxy-6a-methylpregn-4-en-20-one occurred.
  • the product was isolated by filtration, washed consecutively with water and acetone and dried under vacuum to give 8.7 g. product. The product was recrystallized from a hot 1:1 acetone-water mixture.
  • the purity of the compound is substantiated by the presence of one spot with R; 0.5 on silica gel G thin-layerchromatography using the system isopropyl alcohol-waterammonia (7:2:1).
  • the spot is made visible by spraying with sulfuric acid and heating to C.
  • This compound when substituted in the procedure of Example 1, is productive of biscyclohexylammonium- Zip-phosphato-17a-caproyloxy-6a-methylpregn 4 en- 20-one, which is converted to the corresponding disodium salt, disodium 3fi-phosphato-17a-caproyloxy-6u-methylpregn-4-en-20-one, by the procedure of the last paragraph of Example 1.
  • Example 3 Bis-cyclohexylammonium 343 phosphato- 17a-acetoxypregn-4-en-20-one and the corresponding disodium salts Substituting in Preparation 1, as the starting material 17a-acetoxyprogesterone, there is produced BB-hydroxy- 17u-acetoxy-pregn-4-en-20-one.
  • This compound when substituted in the procedure of Example 1 is productive of bis-cyclohexylammonium-3B-phosphato 17a acetoxypregn-4-en-20-one, which is converted to the corresponding disodium salt, disodium-3p-phosphato-17a-acetoxypregn-4-en-20-one, by the procedure of the last paragraph of Example 1.
  • Example 4 Bis-cyclohexylammonium 313 phosphato- 17a acetoxy 6 methylpregna 4,6 diene 20 one and the corresponding disodium salts Substituting in Preparation 1, as the starting material 17a-acetoxy-6-methylpregna-4,6-dien-3,20-dione, there is produced 36 hydrox 17 acetoxy 6 methylpregna 4,6 diene 20 one.
  • This compound when substituted in the procedure of Example 1, is productive of bis cyclohexylammonium 313 phosphato 17aacetoxy 6 methylpregna 4,6 diene 20 one, which is converted to the corresponding disodium salt, disodium 3B phosphato 17a acetoxy 6 methylpregna- 4,6-diene 3,20 dione, by the procedure of the last paragraph of Example 1.
  • Example 5 Bis cyclohexylammonium 3p phosphato 17a acetoxy 6 methyl 16 methylenepregna 4,6 diene 20 one and the corresponding disodium salts Substituting in Preparation 1, as the starting material 17a acetoxy 6 methyl 16 methylene pregna- 4,6 diene 3,20 dione, there is produced 35 hydroxy- 17u acetoxy 6 methyl 16 methylene pregna- 4,6 diene 20 one.
  • This compound when substituted in the procedure of Example 1 is productive of bis-cyclohexylammonium 35 phosphato 17a acetoxy 6- methyl 16 methylene pregna 4,6 diene 20 -one, which is converted to the corresponding disodium salt, disodium 35 phosphato 17cc acetoxy 6 methyl- 16 methylene pregna 4, 6 -diene 20 one, by the procedure of the last paragraph of Example 1.
  • Example 6 Bis cyclohexylammonium 3/3 phosphate 17a acetoxy 6 chloro pregna 4,6 diene- 20-one and the corresponding disodium salts Substituting in Preparation 1, as the starting material 17oz acetoxy 6 chloro pregna 4,6 diene 3,20- dione, there is produced 3 3 hydroxy 17a acetoxy-6- chloro pregna 4,6 diene 20 one.
  • the compounds of this invention in the form of their cyclic ammonium salts or alkali metal salts find use in the treatment of humans and other mammals and animals as progestational gents. Their unique advantages of improved biological response permits under many circumstances reduced side effects; and generally provides for an improved biochemical control of the individual under treatment.
  • the following formulations are representative, and variations in quantities, proportions, concentrations, and size of dosage form can be varied according to the circumstances as well occur readily to those skilled in the art.
  • Disodium 3,6 phosphato 171x acetoxy 6amethylpregn 4 en 20 one mg 50 Sodium citrate mg 5 Benzyl alcohol mg 9 Sodium chloride q.s. to isotonicity. Hydrochloric acid q.s. to pH 7.5. Water for injection q.s ml 1
  • the dosage can vary from 0.2 to 10 mg. of the C phosphate ester material per kilo of body weight of the individual under treatment. The dosage may be repeated, at a frequency and for a duration that can readily be determined by the skilled physician or veterinarian.
  • Oral dosages such as, for example, the tablet of Table I or capsules and lozenges or the like, can contain from about 2 to about 100 mg. of the C -phosphate ester of this invention.
  • Suitable treatments with such dosage forms of this invention and within the purview of this invention include the use of fractional or multiple forms. Scored tablets are useful for fractional dosages.
  • Solutions suitable for injection such as, for example, that shown in Table II can contain from about 2 to about 200 mg. per ml. of the C -phosphate ester of this invention.
  • Suitable treatments with such solutions include, of course, the administration of suitable quantities of the solution and salts thereof.
  • a compound according to claim 1 in which R is methyl, R is acetyl and R is CH 4.
  • a process which comprises treating a steroid A -3B-ol of the androstane series, pregnane series, alkylated androsttane series and alkylated pregnane series with a tri-alkylamine, H PO and trichloroacetonitrile to produce the corresponding A -3-phosphate.
  • An oral composition in dosage unit form for modifying the fertility period in animals comprising from about 2 to about 200 mg. per dosage unit of a salt of a compound of the formula of claim 1.
  • a sterile aqueous solution suitable for injection comprising from about 5 to about 200 mg. per ml. of a salt of a compound of the formula of claim 1.
  • a method for effecting the control of the fertility period in an animal which comprises administering a dose of from about 0.2 to about 10 mg. per kilo of body weight of said animal of a salt of a compound of the formula of claim 1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US544378A 1966-04-22 1966-04-22 Steroid esters Expired - Lifetime US3475537A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54437866A 1966-04-22 1966-04-22

Publications (1)

Publication Number Publication Date
US3475537A true US3475537A (en) 1969-10-28

Family

ID=24171926

Family Applications (1)

Application Number Title Priority Date Filing Date
US544378A Expired - Lifetime US3475537A (en) 1966-04-22 1966-04-22 Steroid esters

Country Status (6)

Country Link
US (1) US3475537A (mo)
BE (1) BE697366A (mo)
FR (1) FR7230M (mo)
GB (1) GB1159334A (mo)
IL (1) IL27669A (mo)
NL (1) NL6703173A (mo)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2928849A (en) * 1953-11-20 1960-03-15 Leo Ab High-molecular weight derivatives of steroids containing hydroxyl groups and method of producing the same
NL6404873A (mo) * 1963-05-01 1964-11-02

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2928849A (en) * 1953-11-20 1960-03-15 Leo Ab High-molecular weight derivatives of steroids containing hydroxyl groups and method of producing the same
NL6404873A (mo) * 1963-05-01 1964-11-02

Also Published As

Publication number Publication date
NL6703173A (mo) 1967-10-23
GB1159334A (en) 1969-07-23
FR7230M (mo) 1969-09-01
DE1643169B2 (de) 1975-09-18
DE1643169A1 (de) 1971-05-13
BE697366A (mo) 1967-10-23
IL27669A (en) 1971-04-28

Similar Documents

Publication Publication Date Title
US3318926A (en) 7alpha-methyl-16alpha-hydroxy-estrones
US3714352A (en) Method of inducing anaesthesia
US3519660A (en) Aldehydes of the pregnane series and derivatives thereof
US3190880A (en) 17-tetrahydropyranyl ethers of androstanes
US3475537A (en) Steroid esters
US3422193A (en) 17-mono esters of corticoids
IE832337L (en) Pregnane compounds
US3696091A (en) Novel cardiac-active principles of the cardenolide glycoside class
US3780070A (en) 4-azido-17alpha-alkinyl-4-gonen-17beta-ol-3-ones and method for their preparation
US2868811A (en) 3beta-acyloxy-17beta-hydroxy-17alpha-ethynyl-5-androstenes and androstanes and theirpreparation
EP0665238B1 (en) Corticoid derivatives and pharmaceutical and cosmetic compositions
US3342682A (en) Oral compositions containing 3-enol ethers of progesterone or 6-methyl derivatives thereof and method of using the same
US3127430A (en) 17alpha-methyl-1, 5-androstadienes-17beta-ol-3-one and derivatives thereof
US3212969A (en) 16-methyl-19-nor-delta4, 6-pregnadiene-3, 20-dione
US3296075A (en) 17alpha-acyloxy-16-methylene-pregn-4-ene-3, 20-diones, pharmaceutical preparations containing same, and intermediate thereto
US3115440A (en) 3-enolethers of free and esterified 17alpha-ethynyl-19-nortestosterone
US3803132A (en) Novel steroid ester
US3388139A (en) 3-enol ethers of progesterone and 6-methyl derivatives thereof
US3591611A (en) 3-oxygenated-17-ureido-androstanes and process
US3488346A (en) 17-alpha-substituted-6-alpha-methyl-pregn-4-en compounds
US3366653A (en) Method of preparing steroids
US3586669A (en) Orally active anti-estrogenic compounds
US3260733A (en) 1beta-methyl steroids
US3468880A (en) 17-substituted 3-(p-methoxybenzenesulfonoxy)androst-5-enes
US3200115A (en) 17-tetrahydropyranyl ethers of 3-desoxy-and 19-nor-3-desoxy-delta2-androstenes